Chimerix, Inc. (NASDAQ:CMRX) Shares Sold by Monaco Asset Management SAM

Monaco Asset Management SAM lessened its position in Chimerix, Inc. (NASDAQ:CMRX - Free Report) by 33.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,820,792 shares of the biopharmaceutical company's stock after selling 1,400,782 shares during the quarter. Chimerix accounts for 1.4% of Monaco Asset Management SAM's portfolio, making the stock its 8th largest position. Monaco Asset Management SAM owned about 3.14% of Chimerix worth $9,816,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in CMRX. Peapod Lane Capital LLC purchased a new position in Chimerix during the 4th quarter valued at about $2,626,000. Assenagon Asset Management S.A. boosted its stake in Chimerix by 154.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock worth $2,846,000 after purchasing an additional 496,823 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock worth $321,000 after purchasing an additional 138,098 shares in the last quarter. Valeo Financial Advisors LLC lifted its stake in Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock valued at $509,000 after acquiring an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC acquired a new stake in Chimerix during the 4th quarter valued at approximately $221,000. Institutional investors own 45.42% of the company's stock.

Remove Ads

Analysts Set New Price Targets

CMRX has been the subject of several analyst reports. Jefferies Financial Group reiterated a "hold" rating and issued a $8.50 target price (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com assumed coverage on shares of Chimerix in a report on Saturday. They issued a "hold" rating for the company. Wedbush reissued a "neutral" rating and issued a $8.55 price target (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $8.55 target price (down previously from $11.00) on shares of Chimerix in a report on Wednesday, March 5th.

Insider Buying and Selling at Chimerix

In related news, CEO Michael T. Andriole sold 7,370 shares of the company's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. This represents a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 20,760 shares of company stock valued at $91,175 over the last 90 days. 13.10% of the stock is owned by insiders.

Chimerix Trading Up 0.1 %

NASDAQ CMRX traded up $0.01 during trading hours on Tuesday, reaching $8.48. The company had a trading volume of 1,495,439 shares, compared to its average volume of 2,077,685. The stock has a 50-day moving average of $4.94 and a 200 day moving average of $2.64. Chimerix, Inc. has a 1-year low of $0.75 and a 1-year high of $8.48. The stock has a market capitalization of $762.66 million, a P/E ratio of -9.02 and a beta of 0.32.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.